Dr. Gary Slatko is a seasoned clinician executive and medical strategist with over 35 years of leadership experience across medical affairs, clinical development, and regulatory strategy for medical products.

As a physician with deep expertise in drug safety, risk management, and product lifecycle strategy, Dr. Slatko brings a unique blend of clinical, regulatory, and business insights to the development and commercialization of pharmaceuticals and AI-enabled medical devices. A former FDA regulator, he served as an Office Director at the U.S. Food and Drug Administration, where he led national initiatives on Risk Evaluation and Mitigation Strategies (REMS) and medication safety policy.

Dr. Slatko now advises medical product companies, investors, and executive leadership teams on regulatory strategy, medical affairs initiatives, and risk-benefit optimization. He is widely recognized as a thought leader in medical product safety and serves as a trusted partner to organizations advancing innovation in life sciences and healthcare technology.

He has held senior leadership positions across both public and private sectors, including Chief Medical Officer roles at DermaSensor, Aquestive Therapeutics and ParagonRx. His expertise spans Phase I–IV pharmaceutical programs, NDA/510(k) submissions, evidence generation strategies, labeling optimization, and scientific communications. He is also a published author of foundational textbooks on pharmaceutical risk management and post-marketing safety.

Earlier in his career, Dr. Slatko held executive roles in medical affairs and disease management at GlaxoSmithKline as Vice President of Care Management and at AstraZeneca as Vice President of Medical Services.